Literature DB >> 12855268

Comparison of stomach cancer incidence and survival in four continents.

A Verdecchia1, A Mariotto, G Gatta, M T Bustamante-Teixeira, W Ajiki.   

Abstract

The aim of this study was to compare stomach cancer incidence and survival rates between four very distinct areas: Campinas (Brasil), Latin America, Iowa (USA), Northern America, Varese (Italy), Europe and Osaka (Japan) in Asia, and determine which of the differences are due to variations in the case mix and which are due to the care received. A proportional hazards regression method was applied to the relative survival rates to obtain geographical differences that were adjusted for age, gender, period of diagnosis, sub-site and stage. Age, gender, period and stage explained most of the variability between the areas (50-100% excess risk of death with respect to Osaka) in the survival rates for stomach cancer patients. In Iowa and Varese, information on the sub-site fully explained the remaining variability. The large survival differences between the four areas were almost totally due to the different case mixes of the stomach cancer patients. The importance of stage indicates that diagnostic delay may be a major clinical factor affecting survival.

Entities:  

Mesh:

Year:  2003        PMID: 12855268     DOI: 10.1016/s0959-8049(03)00360-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  27 in total

1.  Are we making progress in diagnosing and preventing gastrointestinal cancers?

Authors:  Jelle Haringsma; Nicoline C M van Heel; Ernst J Kuipers
Journal:  Therap Adv Gastroenterol       Date:  2010-07       Impact factor: 4.409

Review 2.  Locally advanced gastroesophageal junction tumor: a treatment dilemma.

Authors:  Noman Ashraf; Sarah Hoffe; Richard Kim
Journal:  Oncologist       Date:  2015-01-05

3.  Stomach cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.

Authors:  Melissa A Jim; Paulo S Pinheiro; Helena Carreira; David K Espey; Charles L Wiggins; Hannah K Weir
Journal:  Cancer       Date:  2017-12-15       Impact factor: 6.860

4.  IL-11 is a parietal cell cytokine that induces atrophic gastritis.

Authors:  Meegan Howlett; Heather V Chalinor; Jon N Buzzelli; Nhung Nguyen; Ian R van Driel; Katrina M Bell; James G Fox; Eva Dimitriadis; Trevelyan R Menheniott; Andrew S Giraud; Louise M Judd
Journal:  Gut       Date:  2011-12-16       Impact factor: 23.059

Review 5.  Gastric cancer treatment: similarity and difference between China and Korea.

Authors:  Kun Yang; Jian-Kun Hu
Journal:  Transl Gastroenterol Hepatol       Date:  2017-04-28

Review 6.  Minimally invasive surgery for gastric cancer in USA: current status and future perspectives.

Authors:  Ashley Russo; Vivian E Strong
Journal:  Transl Gastroenterol Hepatol       Date:  2017-04-30

7.  Regional variation in the management of metastatic gastric cancer in Ontario.

Authors:  A L Mahar; N G Coburn; D J Kagedan; R Viola; A P Johnson
Journal:  Curr Oncol       Date:  2016-08-12       Impact factor: 3.677

8.  The survival difference between gastric cancer patients from the UK and Japan remains after weighted propensity score analysis considering all background factors.

Authors:  Takanobu Yamada; Takaki Yoshikawa; Masataka Taguri; Tsutomu Hayashi; Toru Aoyama; Henry M Sue-Ling; Kiran Bonam; Jeremy D Hayden; Heike I Grabsch
Journal:  Gastric Cancer       Date:  2015-03-12       Impact factor: 7.370

9.  Gastric cancer mortality trends in Spain, 1976-2005, differences by autonomous region and sex.

Authors:  Esther García-Esquinas; Beatriz Pérez-Gómez; Marina Pollán; Elena Boldo; Pablo Fernández-Navarro; Virginia Lope; Enrique Vidal; Gonzalo López-Abente; Nuria Aragonés
Journal:  BMC Cancer       Date:  2009-09-28       Impact factor: 4.430

10.  Incidence and survival of stomach cancer in a high-risk population of Chile.

Authors:  Katy Heise; Enriqueta Bertran; Marcelo E Andia; Catterina Ferreccio
Journal:  World J Gastroenterol       Date:  2009-04-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.